Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-directed Dosing of Fluoropyrimidines
NCT02324452Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2015
- Primary completion
- Jan 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Open-label trial of capecitabine and fluorouracil in Neoplasm (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence of severe treatment-related toxicity (CTC grade 3 to 5) at 1 year. Started Mar 2015; status: completed.
02
Drugs
capecitabinefluorouracil
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT02324452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324452.